Datapoint: FDA Approves Abecma for Multiple Myeloma

The FDA last week approved Bristol Myers Squibb’s and bluebird bio’s Abecma for the treatment of multiple myeloma in patients who have not responded to at least four previous rounds of treatment. Abecma is the first CAR-T cell therapy approved for multiple myeloma. This is the second CAR-T therapy for Bristol Myers, following Breyanzi’s lymphoma nod in February. Early data shows Breyanzi is currently covered for 9% of all insured lives, with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/29/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 14

Datapoint: Ochsner to Launch MA Org in Louisiana

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today